PacBio's (PACB) strong product demand and continued focus on R&D raise optimism about the stock.

RVTY's strong product portfolio raises optimism about the stock.

QDEL's strong product portfolio raises optimism about the stock.

NARI continues to gain from its expanded product portfolio. However, continued loss at the operating level raises concern.

CAH gains from a solid pharmaceutical segment and a diversified product portfolio. However, regulatory setbacks are a concern.

Innovations and a robust diabetes market outlook raise investors' optimism for TNDM.

STE's strong prospects in the healthcare business arm bode well for investors.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

GKOS continues to benefit from a robust demand for its products as well as expansion in new markets. A strong development pipeline raises optimism.

Investors remain optimistic about Patterson Companies on the back of its broad product line.